Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16190 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Ditte B Iversen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Anticoagulants, ATP Binding Cassette Transporter, Subfamily B, Member 1, Dicloxacillin, Drug Interactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden, Lundbeck Foundation, Odense University Hospital.
Themen: Schlaganfall
Abstract (Originalsprache)
Aim
We aimed to assess if dicloxacillin/flucloxacillin reduces the therapeutic efficacy of direct oral anticoagulants (DOACs) and the underlying molecular mechanism.
Methods
In a randomized, crossover study, we assessed whether dicloxacillin reduces oral absorption of drugs through P‐glycoprotein (P‐gp) during 10 and 28 days of treatment. To study the impact of dicloxacillin/flucloxacillin on intestinal and hepatic expression of P‐gp in vitro, we usd LS174T cells and 3D spheroids of primary human hepatocytes. Finally, we used nationwide Danish health registries and the UK's Clinical Practice Research Datalink to estimate hazard ratios (HRs) for the risk of stroke and systemic embolism following dicloxacillin/flucloxacillin exposure among DOAC users, using phenoxymethylpenicillin and amoxicillin as active comparators.
Results
Dicloxacillin reduced the area under the curve of dabigatran to a geometric mean ratio 10 days of 0.67 (95% confidence interval [CI]: 0.42–1.1) and geometric mean ratio 28 days of 0.72 (95% CI: 0.39–1.4), suggesting reduced oral absorption via increased P‐gp expression. In vitro, dicloxacillin raised P‐gp expression in both intestinal and liver cells, while flucloxacillin only affected liver cells. In the pharmacoepidemiologic study, dicloxacillin and flucloxacillin were not associated with increased risk of stroke/systemic embolism (dicloxacillin vs . phenoxymethylpenicillin HR: 0.93, 95% CI: 0.72–1.2; flucloxacillin vs . amoxicillin HR: 0.89, 95% CI: 0.51–1.5).
Conclusions
Dicloxacillin increases expression of intestinal P‐gp, leading to reduced oral absorption of dabigatran. However, concomitant use of dicloxacillin/flucloxacillin was not associated with stroke and systemic embolism among DOAC users, suggesting no clinical impact from the drug–drug interaction between dicloxacillin/flucloxacillin and DOACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
- Signatope GmbH, Reutlingen, Germany.
- NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Ditte B Iversen, Ann-Cathrine Dalgård Dunvald, Martin Thomsen Ernst, Shahab Abtahi, Patrick Souverein, Olaf Klungel, Flemming Nielsen, Kim Brøsen, Helen S Hammer, Oliver Pötz, Per Damkier, Erkka Järvinen, Anton Pottegård, Tore B Stage
Förderung
- Novo Nordisk Fonden
- Lundbeck Foundation
- Odense University Hospital
- Odense Universitetshospital
Zitieren
APA
Iversen, D. B., Dunvald, A. D., Ernst, M. T., Abtahi, S., Souverein, P., Klungel, O., Jeppesen, G. B., Nielsen, F., Brøsen, K., Hammer, H. S., Pötz, O., Damkier, P., Järvinen, E., Pottegård, A., & Stage, T. B. (2024). Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16190
Vancouver
Iversen DB, Dunvald AD, Ernst MT, Abtahi S, Souverein P, Klungel O, et al. Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16190
BibTeX
@article{Iversen2024,
author = {Iversen, Ditte B and Dunvald, Ann-Cathrine Dalgård and Ernst, Martin Thomsen and Abtahi, Shahab and Souverein, Patrick and Klungel, Olaf and Jeppesen, Glenn Brøde and Nielsen, Flemming and Brøsen, Kim and Hammer, Helen S and Pötz, Oliver and Damkier, Per and Järvinen, Erkka and Pottegård, Anton and Stage, Tore B},
title = {Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16190}
}
EUVIMED